Get In Touch

The modification of peptide, protein, and non-peptide with the linkage of one or more polyethylene glycol (PEG) chains is known as PEGylation. The polymer formed through PEGylation is non-immunogenic, non-antigenic, nontoxic, and highly soluble in water. PEG-drug conjugates offer several advantages over non-conjugated drugs such as elimination or reduction of protein immunogenicity, prolonged half-life, and less degradation by metabolic enzymes. PEGylation was first described by Davies and Abuchowsky in the 1970s. The process has been expanded and developed since then. A wide range of enzymatic and chemical methods for conjugation are available presently. The U.S. FDA has approved various PEGylated therapeutics for the treatment of diseases including autoimmune diseases (multiple sclerosis, gout, and Crohn's disease), hepatitis C, hepatitis B, cancer, hemophilia, anemia associated with chronic kidney disease, and neovascular age-related macular degeneration. 

PEGylated protein therapeutics is projected to be a highly lucrative market in terms of revenue, with over 10 PEGylated drugs approved by the U.S FDA and 20 drugs in clinical trials. First generation PEGylated drugs were obtained through random PEGylation. Oncaspar and Adagen are two examples. Most of the drugs in clinical trials are PEGylated with larger PEGs compared to first generation therapeutics in order to increase the half-life and decrease the frequency of administration of these therapeutics. Bayer, Novo Nordisk, and Baxalta have a total of four long-acting hemophilia drugs based on PEGylated recombinant coagulation factors in phase III clinical trials. These promising ongoing clinical trials are expected to provide significant opportunities in the market during the forecast period. 

The global PEGylated protein therapeutics market can be segmented based on type of PEGylation, application, distribution channel, and region. In terms of type of PEGylation, the market can be bifurcated into random PEGylation and site specific PEGylation. Based on application, the global PEGylated protein therapeutics market can be classified into cancer, autoimmune diseases, hepatitis, hemophilia, kidney disorder, and others. In terms of distribution channel, the PEGylated protein therapeutics market can be divided into hospital pharmacies, retail pharmacies, and online pharmacies. In terms of region, the global PEGylated protein therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. 

North America and Europe are anticipated to be attractive PEGylated protein therapeutics market. Well-established health care infrastructure and funding from public and private sectors for R&D are projected to propel the market in these regions. Acceptance of technologically advanced devices and novel drugs with ongoing clinical trials in PEGylated therapeutics are expected to drive the market in North America. Asia Pacific is expected to account for a significant share of the global market in terms of revenue during the forecast period. Rise in support from governing bodies and the private sector in developing effective and novel therapeutics and distribution network is anticipated to drive the PEGylated protein therapeutics market in the region. Moreover, high prevalence of chronic and rare diseases in Asia Pacific offers large opportunities to players operating in the PEGylated protein therapeutics market. Japan and Australia are well-established markets in Asia Pacific; however, emerging economies such as China and India present significant opportunities in the PEGylated protein therapeutics market in the region. Other regions such as Middle East & Africa and Latin America are anticipated to be prospective markets for PEGylated protein therapeutics in the near future due to the high adoption rate of advanced therapeutics and the rapidly developing health care industry in the regions.

Major players operating in the global PEGylated protein therapeutics market include AstraZeneca plc, Pfizer, Inc., UCB S.A., Amgen, Inc., Merck & Company, Inc., F. Hoffmann-La Roche Ltd., Shire plc, Biogen, Inc., and Horizon Pharma plc.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Pegylated Protein Therapeutics Market

Pre Book